A farewell to Ozzy, Coke's sugar high, another vaccine shake-up: The week in review
Health Secretary Robert F. Kennedy Jr. took another step toward overhauling the nation's vaccine policy when he approved the removal of thimerosal, a mercury-based preservative, from all flu vaccines despite widespread agreement in the medical community that the preservative is safe. Kennedy signed off on a recommendation from the Advisory Committee on Immunization Practices, a panel he replaced with his own appointed members in June, to stop distributing vaccines containing thimerosal, which has long been targeted by anti-vaccine groups.
An operatic honor for Melania
Republican lawmakers are working on a Kennedy Center production of their own: renaming the center's Opera House to the 'First Lady Melania Trump Opera House.' The House Appropriations Committee, whose spending bill funds the iconic performing arts venue in Washington, voted 33-25 for the change. Lawmakers have already agreed to spend $256.7 million on improvements to the center sought by President Donald Trump, who ousted much of the Kennedy Center's board after he took office and appointed himself chairman. He has criticized some of the center's performances and said in one visit that he 'never liked 'Hamilton' very much.'
A sweet twist to the Cola wars
Cane sugar: It's the real thing. A Coca-Cola made with cane sugar − not high-fructose corn syrup − is coming to the United States this fall, the company announced, just like the Coke you find overseas, including Mexico. (The long-running debate over which tastes better, U.S. Coke or Mexican Coke, has been a fierce one). The news doesn't come as a compete surprise; President Donald Trump had made a case for cane sugar Coke on social media in mid-July − 'You'll see. It's just better!' Also, not to be outdone, Pepsi announced it is launching Pepsi Prebiotic Cola this fall, in Original Cola and Cherry Vanilla, containing 5 grams of cane sugar and 3 grams of prebiotic fiber.
Ozzy Osbourne, the 'Prince of Darkness,' is dead
The heavy metal world has lost one of its most beloved characters, Ozzy Osbourne, at age 76, only weeks after reuniting with his original band, Black Sabbath, in England for a farewell show. Osbourne, who was infamous for his hard living (and for biting the head off a bat), exploded into stardom in a solo career and later branched into reality TV with MTV's 'The Osbournes' in the early 2000s. In 2020, he revealed he had Parkinson's disease. In a just-announced new memoir, 'Last Rites,' arriving Oct. 7, Osbourne says: 'Look, if it ends tomorrow, I can't complain. I've been all around the world. … I've done good, and I've done bad. But right now, I'm not ready to go anywhere.'
Remembering Ozzy Osbourne: Life on the 'Crazy Train': The metal icon through the years
All bets for 2026 are on Scottie Scheffler
Scottie Scheffler, fresh off a dominating win at the British Open July 20, is at the top of his game, and you can expect he'll be there for awhile. Scheffler, 29, who also captured the PGA Championship in May and now needs only a U.S. Open victory to enter the elite group of golfers who have won the sport's grand slam of all four major championships, is now the odds-on favorite to win every major in 2026, according to BetMGM. Declared the gaming venture's Matt Wall: 'The comparisons with Tiger Woods certainly don't look out of place right now.' − Compiled by Robert Abitbol
This article originally appeared on USA TODAY: A farewell to Ozzy, Coke's sugar high, the flu fight: Week in review
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.